Evaluation of dihydropyrimidine dehydrogenase activity in South-west Asian, Kenyan and Ghanaian populations

Br J Clin Pharmacol. 2000 Sep;50(3):269-72. doi: 10.1046/j.1365-2125.2000.00242.x.

Abstract

Aims: Dihydropyrimidine dehydrogenase (DPD) reduces endogenous pyrimidines and therapeutic analogues such as the anticancer agent 5-fluorouracil (5FU). Among Caucasian populations DPD activity is highly variable and subject to polymorphic regulation. To evaluate interethnic influence, DPD activity was assessed in South-west Asian, Kenyan and Ghanaian populations.

Methods: DPD activity was determined in peripheral mononuclear cells using[14C]-5-fluorouracil and h.p.l.c. analysis.

Results: A high degree of variation in DPD activity was observed within each population (range CV = 34-48%). Median DPD activity also varied between these populations. South-west Asian and Kenyan subjects exhibited almost identical median values (192 and 193.5 pmol min(-1) mg(-1), respectively), which were similar to Caucasians (median 215 pmol min(-1) mg(-1). A significantly lower median DPD activity (119 pmol min(-1) mg(-1)) was observed in the Ghanaian population.

Conclusions: The similarity in DPD activity between Caucasian, Kenyan and South-west Asian populations suggests that the incidence of 5FU-related toxicity may be comparable in these groups. The pharmacokinetic implications of lower activity amongst Ghanaians needs to be evaluated.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antimetabolites / adverse effects
  • Antimetabolites / pharmacokinetics
  • Asia
  • Asian People
  • Black People
  • Chromatography, High Pressure Liquid
  • Dihydrouracil Dehydrogenase (NADP)
  • Female
  • Fluorouracil / adverse effects
  • Fluorouracil / pharmacokinetics
  • Ghana
  • Humans
  • Kenya
  • Male
  • Oxidoreductases / metabolism*
  • White People

Substances

  • Antimetabolites
  • Oxidoreductases
  • Dihydrouracil Dehydrogenase (NADP)
  • Fluorouracil